These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
801 related articles for article (PubMed ID: 37511431)
1. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment. Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431 [TBL] [Abstract][Full Text] [Related]
2. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. Quiroga D; Lyerly HK; Morse MA Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067 [TBL] [Abstract][Full Text] [Related]
3. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787 [TBL] [Abstract][Full Text] [Related]
4. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer. Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107 [TBL] [Abstract][Full Text] [Related]
5. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. Inamori K; Togashi Y; Fukuoka S; Akagi K; Ogasawara K; Irie T; Motooka D; Kobayashi Y; Sugiyama D; Kojima M; Shiiya N; Nakamura S; Maruyama S; Suzuki Y; Ito M; Nishikawa H JCI Insight; 2021 May; 6(9):. PubMed ID: 33755600 [TBL] [Abstract][Full Text] [Related]
6. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F Front Immunol; 2021; 12():808964. PubMed ID: 35095898 [TBL] [Abstract][Full Text] [Related]
8. Application of immune checkpoint inhibitors in colorectal cancer. Wang L; Huang C Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736 [TBL] [Abstract][Full Text] [Related]
10. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Picard E; Verschoor CP; Ma GW; Pawelec G Front Immunol; 2020; 11():369. PubMed ID: 32210966 [TBL] [Abstract][Full Text] [Related]
11. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906 [TBL] [Abstract][Full Text] [Related]
12. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability. Wu T; Zhang X; Liu X; Cai X; Shen T; Pan D; Liang R; Ding R; Hu R; Dong J; Li F; Li J; Xie L; Wang C; Geng S; Yang Z; Xing L; Li Y BMC Med; 2023 Apr; 21(1):161. PubMed ID: 37106440 [TBL] [Abstract][Full Text] [Related]
13. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target. Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115 [TBL] [Abstract][Full Text] [Related]
14. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635 [TBL] [Abstract][Full Text] [Related]
15. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Lin A; Zhang J; Luo P Front Immunol; 2020; 11():2039. PubMed ID: 32903444 [TBL] [Abstract][Full Text] [Related]
16. Presence of Tim3 Klapholz M; Drage MG; Srivastava A; Anderson AC J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692 [TBL] [Abstract][Full Text] [Related]
17. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142 [TBL] [Abstract][Full Text] [Related]
19. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer. Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G Front Immunol; 2023; 14():1298524. PubMed ID: 38187388 [TBL] [Abstract][Full Text] [Related]